Last reviewed · How we verify
PAZOPANIB HYDROCHLORIDE
Pazopanib inhibits multiple tyrosine kinases, blocking angiogenesis and tumor growth.
At a glance
| Generic name | PAZOPANIB HYDROCHLORIDE |
|---|---|
| Target | VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2009 |
Mechanism of action
Pazopanib works by inhibiting several tyrosine kinases that are involved in the growth and survival of blood vessels and tumors. By blocking these receptors, it prevents the formation of new blood vessels (angiogenesis) and slows down the growth of certain tumors.
Approved indications
Boxed warnings
- WARNING: HEPATOTOXICITY Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended [see Warnings and Precautions (5.1) ]. WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended. ( 5.1 )
Common side effects
- Diarrhea
- Hypertension
- Hair color changes
- Nausea
- Fatigue
- Anorexia
- Vomiting
- Decreased weight
- Decreased appetite
- Tumor pain
- Musculoskeletal pain
- Headache
Key clinical trials
- Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (PHASE2, PHASE3)
- Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors (PHASE1)
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery (PHASE3)
- Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors (PHASE2)
- Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer (PHASE1, PHASE2)
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma (NA)
- Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome (PHASE2)
- Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PAZOPANIB HYDROCHLORIDE CI brief — competitive landscape report
- PAZOPANIB HYDROCHLORIDE updates RSS · CI watch RSS